CN112353937A - Fresh agrimony freeze-dried powder composite preparation - Google Patents
Fresh agrimony freeze-dried powder composite preparation Download PDFInfo
- Publication number
- CN112353937A CN112353937A CN202011426374.1A CN202011426374A CN112353937A CN 112353937 A CN112353937 A CN 112353937A CN 202011426374 A CN202011426374 A CN 202011426374A CN 112353937 A CN112353937 A CN 112353937A
- Authority
- CN
- China
- Prior art keywords
- agrimony
- powder
- wound
- freeze
- dried
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000843 powder Substances 0.000 title claims abstract description 77
- 244000307697 Agrimonia eupatoria Species 0.000 title claims abstract description 71
- 235000000125 common agrimony Nutrition 0.000 title claims abstract description 71
- 238000002360 preparation method Methods 0.000 title claims abstract description 44
- 239000002131 composite material Substances 0.000 title description 2
- 206010052428 Wound Diseases 0.000 claims abstract description 91
- 208000027418 Wounds and injury Diseases 0.000 claims abstract description 91
- 239000003814 drug Substances 0.000 claims abstract description 59
- 102000016943 Muramidase Human genes 0.000 claims abstract description 43
- 108010014251 Muramidase Proteins 0.000 claims abstract description 43
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims abstract description 43
- 235000010335 lysozyme Nutrition 0.000 claims abstract description 43
- 229960000274 lysozyme Drugs 0.000 claims abstract description 43
- 239000004325 lysozyme Substances 0.000 claims abstract description 43
- 206010039509 Scab Diseases 0.000 claims abstract description 40
- 230000000694 effects Effects 0.000 claims abstract description 31
- 206010061218 Inflammation Diseases 0.000 claims abstract description 20
- 230000000740 bleeding effect Effects 0.000 claims abstract description 16
- 238000002474 experimental method Methods 0.000 claims abstract description 16
- 230000004054 inflammatory process Effects 0.000 claims abstract description 16
- 230000029663 wound healing Effects 0.000 claims abstract description 10
- 231100000241 scar Toxicity 0.000 claims abstract description 9
- 238000012545 processing Methods 0.000 claims abstract description 7
- 239000008280 blood Substances 0.000 claims abstract description 3
- 210000004369 blood Anatomy 0.000 claims abstract description 3
- 230000035876 healing Effects 0.000 claims description 20
- 238000001035 drying Methods 0.000 claims description 15
- 229940079593 drug Drugs 0.000 claims description 10
- 238000003672 processing method Methods 0.000 claims description 10
- 230000001954 sterilising effect Effects 0.000 claims description 10
- 241001465754 Metazoa Species 0.000 claims description 9
- 208000002847 Surgical Wound Diseases 0.000 claims description 9
- 230000002439 hemostatic effect Effects 0.000 claims description 9
- 208000014674 injury Diseases 0.000 claims description 9
- 230000008733 trauma Effects 0.000 claims description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- 241000726221 Gemma Species 0.000 claims description 8
- 230000000844 anti-bacterial effect Effects 0.000 claims description 7
- 230000002195 synergetic effect Effects 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 6
- 230000015572 biosynthetic process Effects 0.000 claims description 6
- 230000023597 hemostasis Effects 0.000 claims description 5
- 238000004140 cleaning Methods 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 4
- 229940126532 prescription medicine Drugs 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 3
- 239000000645 desinfectant Substances 0.000 claims description 3
- 238000011084 recovery Methods 0.000 claims description 3
- 230000004044 response Effects 0.000 claims description 3
- 241000196324 Embryophyta Species 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 2
- 230000023555 blood coagulation Effects 0.000 claims description 2
- 210000004204 blood vessel Anatomy 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 238000007710 freezing Methods 0.000 claims description 2
- 230000008014 freezing Effects 0.000 claims description 2
- 239000007789 gas Substances 0.000 claims description 2
- 230000002757 inflammatory effect Effects 0.000 claims description 2
- 229960002523 mercuric chloride Drugs 0.000 claims description 2
- LWJROJCJINYWOX-UHFFFAOYSA-L mercury dichloride Chemical compound Cl[Hg]Cl LWJROJCJINYWOX-UHFFFAOYSA-L 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 230000001681 protective effect Effects 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims description 2
- 238000004659 sterilization and disinfection Methods 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 231100000331 toxic Toxicity 0.000 claims description 2
- 230000002588 toxic effect Effects 0.000 claims description 2
- 230000000472 traumatic effect Effects 0.000 claims description 2
- 238000009777 vacuum freeze-drying Methods 0.000 claims description 2
- 238000012795 verification Methods 0.000 claims description 2
- 229940126680 traditional chinese medicines Drugs 0.000 claims 1
- 238000004321 preservation Methods 0.000 abstract description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 206010067482 No adverse event Diseases 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000032544 Cicatrix Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 206010061926 Purulence Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01017—Lysozyme (3.2.1.17)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/13—Preparation or pretreatment of starting material involving cleaning, e.g. washing or peeling
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
Abstract
The invention relates to the technical field of fresh traditional Chinese medicine processing, in particular to a freeze-dried powder of agrimony which is prepared by taking fresh agrimony traditional Chinese medicine and processing the fresh agrimony through low-temperature preservation by modern biotechnology. And mixing the freeze dried agrimony powder and lysozyme to form the medicine preparation. After the medicament is taken for about 1 minute, blood can be stopped at the newly formed bleeding wound surface, the wound surface can be converged and dried to form a hard scab scar layer, the medicinal powder layer can be peeled off or easily removed in about 5 hours, only a thin scab scar layer is left, and inflammation under scab is not easily generated. The lysozyme in the preparation has obvious coordination and synergism function when being added by 0.1-0.4 percent, the best synergism function when being added by 0.3-0.4 percent, the wound healing time is shortened, the wound healing time can be shortened by about 17 percent in a wound model experiment of a white rat with the diameter of 1.5CM compared with the wound healing time without lysozyme, and the early wound healing and scabbing effects are obviously accelerated.
Description
The technical field of the invention is as follows:
the invention relates to the technical field of fresh traditional Chinese medicine processing, in particular to freeze-dried fresh agrimony medicine powder which is prepared by taking fresh agrimony (the name of the agrimony latin is the same under the Herba Agrimoniae) traditional Chinese medicine and performing low-temperature fresh-keeping processing by using modern biotechnology. Then combining the freeze-dried powder of the fresh agrimony and Lysozyme (Latin name: Lysozyme, the same below) into a new pharmaceutical preparation.
Background
The traditional processing method of the agrimony traditional Chinese medicine comprises the following steps: [ PREPARATION METHOD ] removing residual root and impurities, cleaning, moistening slightly, cutting, and drying. [ FUNCTIONS AND INDICATIONS ] can astringe to stop bleeding, check malaria, stop dysentery, remove toxicity, and tonify deficiency. [ DOSAGE AND ADMINISTRATION ] 6-12 g. Proper dosage is for external application. Pounding and applying. { page 158 of the auxiliary description of Chinese pharmacopoeia (2010 version) (herbs and decoction pieces). Because the traditional Chinese medicine processing method has large loss and little retention of the effective ingredients of the agrimony, the agrimony has unobvious effects of convergence, hemostasis and wound healing in the treatment of surgical wounds.
Summary of the invention
The invention relates to a new medicinal preparation which is prepared by combining fresh leaves and stems of a traditional Chinese medicine, namely hairyvein agrimony, with lysozyme and fresh medicinal freeze-dried powder which is processed by using modern biotechnology and is preserved at a low temperature. The preservation and the application of the active ingredients of the medicine are greatly improved after the fresh agrimony is processed at low temperature, and the processed medicine can be directly used for stopping bleeding, astringing, healing wound and resisting inflammation for treating surgical wound, and has quick response and good effect. The addition of the adjuvant lysozyme increases the anti-inflammation (the antibacterial range is enlarged) and the stability (lysozyme has antiseptic effect) of the medicine in the preparation, and has synergistic effect.
The preparation is also effective in treating red swelling of sore and furuncle.
The technical scheme of the invention is as follows:
firstly, obtaining raw materials: (in this case, fresh agrimony is selected from Ningxiang county and surrounding areas of Hunan province)
Fresh leaves and stems of herba et Gemma Agrimoniae (taken alone or in whole plant) are called as fresh herba et Gemma Agrimoniae, and is prepared by cleaning fresh herba et Gemma Agrimoniae with clean water, removing external water (drying by spin-drying equipment), sterilizing by ultraviolet irradiation (or rapidly sterilizing with alcohol with concentration of below 80% or sterilizing with disinfectant such as mercuric chloride, etc.), and sterilizing for 1 hr or less.
Secondly, the processing method comprises the following steps:
1. processing cleaned and sterilized fresh herba et Gemma Agrimoniae into wet powder with high water content (hereinafter referred to as "wet powder") at normal temperature to-199 deg.C (quick freezing with liquid nitrogen). Then putting the wet powder (or cleaned and sterilized fresh agrimony which can be quickly frozen by liquid nitrogen) into a freeze dryer for vacuum freeze drying (about 10 hours the medicine effect is good, about 20 hours the medicine powder is dry, the medicine effect is good) to prepare freeze-dried powder, which is hereinafter referred to as 'freeze-dried agrimony powder'.
In addition: the wet powder can be added with a certain amount of lysozyme (with good effect within 0.05% -0.5%, or with concentration within 3%), and then freeze-dried by a freeze dryer to prepare freeze-dried powder.
Third, preparation components and synthetic technical scheme
The preparation comprises the following components: 97-99.999% of freeze-dried agrimony powder and 0.001-3% of lysozyme (0.05-0.5% of lysozyme has good effect).
The freeze-dried agrimony powder and the lysozyme are mixed uniformly according to a proportion (preferably in a vacuum environment or under protective gas) to obtain the pharmaceutical preparation.
Fourthly, the fresh agrimony freeze-dried powder and the preparation have the advantages that:
the low-temperature fresh-keeping processing method of the fresh agrimony greatly improves the reservation and application of the active ingredients in the freeze-dried agrimony powder, so that the freeze-dried agrimony powder processed by low-temperature fresh-keeping can be directly used for stopping bleeding, astringing, forming scabs and healing wounds and resisting inflammation, and has quick response and good effect. The agrimony powder processed by the traditional Chinese medicine processing method has unobvious hemostatic, astringent and wound healing effects on wound wounds, and is in dispute.
The freeze-dried agrimony powder and the lysozyme are combined into a medicinal preparation, and the medicinal preparation and the agrimony freeze-dried powder have a synergistic effect in the experimental process. The animal experiment proves that: the lysozyme has obvious coordination and synergism function when being added by 0.1-0.4 percent, the best synergism function when being added by 0.3-0.4 percent, the healing time is shortened, the total healing time can be shortened by about 17 percent in a rat wound model experiment with the diameter of 1.5CM (by adding the lysozyme with the proportion of 0.3-0.4 percent), and the early healing effect is obviously accelerated.
When the agrimony freeze-dried powder and the lysozyme are combined into the medicinal preparation for treating wounds, the convergence, the drying or the scabbing effect of the wound surface of the wound can be obviously observed after the medicinal preparation is used for about 2 hours, the hemostatic effect is obvious, and the wound surface is scabbed and clean in 8-12 hours and generally has no inflammatory phenomenon. When the common trauma medicine and the hairyvein agrimony powder processed by the traditional Chinese medicine processing method are used for treating wounds, the wound surface of the wound can not be observed to be converged within 12 hours, the drying and scabbing effects are achieved, and the hemostatic effect is not obvious. In the experimental data of the traditional trauma medicine, the traditional trauma medicine is effective in hemostasis after being used for about 3 minutes, but the wound surface is wet, hard scab is not formed due to convergence and drying after the traditional trauma medicine is used, and the wound surface cannot be induced by external force and needs to be specially protected (clinically, the wound surface is protected by sterile gauze and is a dangerous period of the wound surface); it can be observed only after about ten hours or 24 hours after the application of the medicine for stopping bleeding to make blood vessel shrink, the formation of platelet hemostatic plug, blood coagulation and formation of hard crust after convergence and drying, and the effect is similar to that of Yunnan white drug powder, fresh agrimony wet powder and dry leaf powder through animal experiment verification (comfortable room temperature and humidity environment). Clinically, the formation of hard scab on the wound surface can be observed only after 1 to 2 days, and the phenomena of inflammation under the scab and scab falling are easy to occur. Therefore, clinically, the medicines are rarely used for treating external wounds alone. The reason why the traditional agrimony prescription medicine has no obvious treatment advantages is that the traditional agrimony prescription medicine is not used (clinically) for treating traumatic hemostasis and healing wounds at present. The freeze-dried agrimony powder (with lysozyme in a proportion of about 1-5 per thousand can be added) is used for stopping blood after being applied for about 1 minute, and the wound surface can be converged and dried to form a hard scab layer (the effect is obvious because the skin capillary of a human body is rich and the bleeding of the external wound surface is much) after the wound surface is dried, the wound surface position can be touched by hands (or instruments) after about 3 minutes, the scab is not easy to fall off, and the medicinal powder layer can automatically fall off or be easily removed after about 5 hours, only a thin scab layer is left (when the medicine is used for the human body or clinically, the phenomenon that the scab is easily caused by the scab thickness of the above or traditional common medicines is not easy to generate, and the wound patient can quickly pass through a dangerous period and enter a recovery period); and the total healing time is shortened. The traditional Chinese medicine composition is obviously different from the traditional common medicine in curative effect, is not possessed by other medicines (containing lysozyme), and is discovered after a large number of experiments. This new discovery has provided ample rationale for combining the two. To summarize: the freeze-dried agrimony powder (which can be added with lysozyme combination) can stop bleeding on a bleeding wound surface within 1-3 minutes and can be converged and dried to form a hard scab layer, which is a new discovery; the combination of the agrimony freeze-dried powder and the lysozyme has a synergistic function, so that the total healing time of a white rat wound model is shortened, and the discovery is also new.
Fifthly, the preparation has the advantages of
1. The preparation has simple and safe components, and omits toxic components in the traditional medicinal preparation for treating the wound.
2. The preparation has small residual scar after the wound is completely healed after the preparation is used for treating surgical wounds, and the scar is not easy to be detected after the external wounds on the superficial layer of the skin are completely healed (about 20 days) (iodine residue cannot be remained in the whole process of the wound treatment, and the iodine residue can cause obvious residual scar after the wound is completely healed).
3. The preparation can promote wound healing and scabbing, and promote wound drying, and the used medicine (about 5 hours) is easy to be removed from the wound; the wound surface scabs in the small-area surgical wound of the skin at the movable joint within 12 hours, the scab is not easy to crack, the wound opening is not easy to be infected, and the phenomena of inflammation and scab inflammation are avoided generally, so that the difficulty that the skin surgical wound at the joint is difficult to heal by the traditional wound medicament treatment is well solved. Is a new medicine with breakthrough therapeutic effect.
4. The two antibacterial factors are combined to achieve the broad-spectrum antibacterial and anti-inflammatory effects.
5. Coordinating and enhancing the effect.
Description of the drawings: the preparation is used by the inventor and other personal experiments, and the advantages are summarized by combining with animal experiments.
Sixth, preparation description
Freeze-dried agrimony powder: stopping bleeding, astringing, healing wound, and resisting inflammation.
Lysozyme: anti-inflammation, sterilization, fresh-keeping and synergistic effect.
The preparation takes the freeze-dried powder of the traditional Chinese medicine hairyvein agrimony as a main medicine, and after lysozyme is added and mixed, the anti-inflammation (the antibacterial range is enlarged) and the stability (the lysozyme has the antiseptic function) of the medicine in the preparation are enhanced; because the fresh powder of the agrimony which is processed in the fresh-keeping way needs to be refrigerated and preserved or frozen to ensure the stability of the medicine, the lysozyme is added for fresh-keeping to enhance the stability of the fresh powder of the agrimony.
The preparation comprises the following components:
[ FUNCTIONS ] can stop bleeding, relieve inflammation, astringe and heal wound.
[ DOSAGE ADMINISTRATION ] 80 mg of a surgical wound model with a diameter of 1.5 cm; proper dosage is for external application.
[ Pharmacology toxicology ] fresh herba Agrimoniae powder has hemostatic effect, and the herba Agrimoniae powder containing herba Agrimoniae tannin has astringent and antiinflammatory effects, so that it has wound healing effect; the fresh powder of the agrimony has an inhibiting effect on gram-negative bacteria; lysozyme is a mucopolysaccharide hydrolase widely distributed in human bodies, can liquefy insoluble polysaccharide of gram-positive bacteria cell walls and hydrolyze the insoluble polysaccharide into soluble mucopeptide, is a natural anti-infection substance with a bactericidal effect, and has the effects of resisting bacteria, viruses and inflammation and accelerating tissue recovery.
[ caution item ] no high-intensity exercise and labor should be performed during the administration period, so as to avoid the phenomena of inflammation and purulence of the wound surface caused by sweat flowing into the wound surface, especially the first 3 days of the administration of the wound surface. For example, the pus-like substance can be removed from the wound surface with water solution before application. Or treating with erythromycin ointment or other disinfectant, preferably washing wound surface with normal saline (0.9% sodium chloride solution), and applying. When the wound is treated, the wound surface does not have iodine residue as much as possible, and the iodine residue can cause obvious scars after the wound is completely healed.
Note description: the preparation is tried by the inventor in person, has been tried by many people voluntarily in the Zufu county of Hunan province and the dam pond county, and has been tried by many people under the guidance of doctors for weekly cleaning, and has good effect. The inventor of the invention obtains the above cautions after observing and visiting the treatment effect of the trial personnel, and no adverse reaction is found after observation and visiting investigation. No adverse reaction is observed after a large number of animal wound model experiments are carried out on the preparation.
[ animal experiments ]
The animal experiment results show that: after the freeze-dried powder of the agrimony added with the lysozyme and the freeze-dried powder of the agrimony not added with the lysozyme are used for treating wounds, the healing effect of the wounds is excellent, and the total healing effect of the freeze-dried powder of the fresh agrimony powder is similar to that of the fresh agrimony powder which is not freeze-dried. The healing speed and the astringency of the wound at the early stage (3 days) are obviously better than those of a Yunnan white drug powder treatment group, a dry leaf powder group and a blank control group, andthe wound and the face are dry, and the inflammation phenomenon is avoided; the mechanical damage area is 1.77cm2The wound (diameter 1.5cm) can be completely healed within 9-12 days (see the table below), which is obviously superior to a blank control group and is slightly superior to a Yunnan white drug group.
Experimental results of trauma model of white rat (laboratory temperature 25 deg.C, + -3 deg.C; humidity 65% + -5%)
Claims (1)
1. The invention relates to a freeze-dried powder of fresh agrimony, which is prepared by processing fresh traditional Chinese medicines of the agrimony (the name of the agrimony latin is Herba Agrimoniae, the same below) into the freeze-dried powder of the fresh agrimony by modern biotechnology. Then combining the freeze-dried powder of the fresh agrimony and Lysozyme (Latin name: Lysozyme, the same below) into a new pharmaceutical preparation.
The technical scheme of the invention is as follows:
firstly, obtaining raw materials: (in this case, fresh agrimony is selected from Ningxiang county and surrounding areas of Hunan province)
Fresh leaves and stems of herba et Gemma Agrimoniae (taken alone or in whole plant) are called as fresh herba et Gemma Agrimoniae, and is prepared by cleaning fresh herba et Gemma Agrimoniae with clean water, removing external water (drying by spin-drying equipment), sterilizing by ultraviolet irradiation (or rapidly sterilizing with alcohol with concentration of below 80% or sterilizing with disinfectant such as mercuric chloride, etc.), and sterilizing for 1 hr or less.
Secondly, the processing method comprises the following steps:
1. processing cleaned and sterilized fresh herba et Gemma Agrimoniae into wet powder with high water content (hereinafter referred to as "wet powder") at normal temperature to-199 deg.C (quick freezing with liquid nitrogen). Then putting the wet powder (or cleaned and sterilized fresh agrimony which can be quickly frozen by liquid nitrogen) into a freeze dryer for vacuum freeze drying (about 10 hours the medicine effect is good, about 20 hours the medicine powder is dry, the medicine effect is good) to prepare freeze-dried powder, which is hereinafter referred to as 'freeze-dried agrimony powder'.
In addition: the wet powder can be added with a certain amount of lysozyme (with good effect within 0.05% -0.5%, or with concentration within 3%), and then freeze-dried by a freeze dryer to prepare freeze-dried powder.
Third, preparation components and synthetic technical scheme
The preparation comprises the following components: 97-99.999% of freeze-dried agrimony powder and 0.001-3% of lysozyme (0.05-0.5% of lysozyme has good effect).
The freeze-dried agrimony powder and the lysozyme are mixed uniformly according to a proportion (preferably in a vacuum environment or under protective gas) to obtain the pharmaceutical preparation.
Fourthly, the fresh agrimony freeze-dried powder and the preparation have the advantages that:
the low-temperature fresh-keeping processing method of the fresh agrimony greatly improves the reservation and application of the active ingredients in the freeze-dried agrimony powder, so that the freeze-dried agrimony powder processed by low-temperature fresh-keeping can be directly used for stopping bleeding, astringing, forming scabs and healing wounds and resisting inflammation, and has quick response and good effect. The agrimony powder processed by the traditional Chinese medicine processing method has unobvious hemostatic, astringent and wound healing effects on wound wounds, and is in dispute.
The freeze-dried agrimony powder and the lysozyme are combined into a medicinal preparation, and the medicinal preparation and the agrimony freeze-dried powder have a synergistic effect in the experimental process. The animal experiment proves that: the lysozyme has obvious coordination and synergism function when being added by 0.1-0.4 percent, the best synergism function when being added by 0.3-0.4 percent, the healing time is shortened, the total healing time can be shortened by about 17 percent in a rat wound model experiment with the diameter of 1.5CM (by adding the lysozyme with the proportion of 0.3-0.4 percent), and the early healing effect is obviously accelerated.
When the agrimony freeze-dried powder and the lysozyme are combined into the medicinal preparation for treating wounds, the convergence, the drying or the scabbing effect of the wound surface of the wound can be obviously observed after the medicinal preparation is used for about 2 hours, the hemostatic effect is obvious, and the wound surface is scabbed and clean in 8-12 hours and generally has no inflammatory phenomenon. When the common trauma medicine and the hairyvein agrimony powder processed by the traditional Chinese medicine processing method are used for treating wounds, the wound surface of the wound can not be observed to be converged within 12 hours, the drying and scabbing effects are achieved, and the hemostatic effect is not obvious. In the experimental data of the traditional trauma medicine, the traditional trauma medicine is effective in hemostasis after being used for about 3 minutes, but the wound surface is wet, hard scab is not formed due to convergence and drying after the traditional trauma medicine is used, and the wound surface cannot be induced by external force and needs to be specially protected (clinically, the wound surface is protected by sterile gauze and is a dangerous period of the wound surface); it can be observed only after about ten hours or 24 hours after the application of the medicine for stopping bleeding to make blood vessel shrink, the formation of platelet hemostatic plug, blood coagulation and formation of hard crust after convergence and drying, and the effect is similar to that of Yunnan white drug powder, fresh agrimony wet powder and dry leaf powder through animal experiment verification (comfortable room temperature and humidity environment). Clinically, the formation of hard scab on the wound surface can be observed only after 1 to 2 days, and the phenomena of inflammation under the scab and scab falling are easy to occur. Therefore, clinically, the medicines are rarely used for treating external wounds alone. The reason why the traditional agrimony prescription medicine has no obvious treatment advantages is that the traditional agrimony prescription medicine is not used (clinically) for treating traumatic hemostasis and healing wounds at present. The freeze-dried agrimony powder (with lysozyme in a proportion of about 1-5 per thousand can be added) is used for stopping blood after being applied for about 1 minute, and the wound surface can be converged and dried to form a hard scab layer (the effect is obvious because the skin capillary of a human body is rich and the bleeding of the external wound surface is much) after the wound surface is dried, the wound surface position can be touched by hands (or instruments) after about 3 minutes, the scab is not easy to fall off, and the medicinal powder layer can automatically fall off or be easily removed after about 5 hours, only a thin scab layer is left (when the medicine is used for the human body or clinically, the phenomenon that the scab is easily caused by the scab thickness of the above or traditional common medicines is not easy to generate, and the wound patient can quickly pass through a dangerous period and enter a recovery period); and the total healing time is shortened. The traditional Chinese medicine composition is obviously different from the traditional common medicine in curative effect, is not possessed by other medicines (containing lysozyme), and is discovered after a large number of experiments. This new discovery has provided ample rationale for combining the two. To summarize: the freeze-dried agrimony powder (which can be added with lysozyme combination) can stop bleeding on a bleeding wound surface within 1-3 minutes and can be converged and dried to form a hard scab layer, which is a new discovery; the combination of the agrimony freeze-dried powder and the lysozyme has a synergistic function, so that the total healing time of a white rat wound model is shortened, and the discovery is also new.
Fifthly, the preparation has the advantages of
1. The preparation has simple and safe components, and omits toxic components in the traditional medicinal preparation for treating the wound.
2. The preparation has small residual scar after the wound is completely healed after the preparation is used for treating surgical wounds, and the scar is not easy to be detected after the external wounds on the superficial layer of the skin are completely healed (about 20 days) (iodine residue cannot be remained in the whole process of the wound treatment, and the iodine residue can cause obvious residual scar after the wound is completely healed).
3. The preparation can promote wound healing and scabbing, and promote wound drying, and the used medicine (about 5 hours) is easy to be removed from the wound; the wound surface scabs in the small-area surgical wound of the skin at the movable joint within 12 hours, the scab is not easy to crack, the wound opening is not easy to be infected, and the phenomena of inflammation and scab inflammation are avoided generally, so that the difficulty that the skin surgical wound at the joint is difficult to heal by the traditional wound medicament treatment is well solved. Is a new medicine with breakthrough therapeutic effect.
4. The two antibacterial factors are combined to achieve the broad-spectrum antibacterial and anti-inflammatory effects.
5. Coordinating and enhancing the effect.
Description of the drawings: the preparation is used by the inventor and other personal experiments, and the advantages are summarized by combining with animal experiments.
Sixth, preparation description
Freeze-dried agrimony powder: stopping bleeding, astringing, healing wound, and resisting inflammation.
Lysozyme: anti-inflammation, sterilization, fresh-keeping and synergistic effect.
97 to 99.999 percent of freeze-dried agrimony powder and 0.001 to 3 percent of lysozyme are combined into a medicinal preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011426374.1A CN112353937A (en) | 2020-12-03 | 2020-12-03 | Fresh agrimony freeze-dried powder composite preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011426374.1A CN112353937A (en) | 2020-12-03 | 2020-12-03 | Fresh agrimony freeze-dried powder composite preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112353937A true CN112353937A (en) | 2021-02-12 |
Family
ID=74537006
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011426374.1A Pending CN112353937A (en) | 2020-12-03 | 2020-12-03 | Fresh agrimony freeze-dried powder composite preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112353937A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006069540A1 (en) * | 2004-12-29 | 2006-07-06 | Ocean University Of China | Burn-treating drug delivery system containing trehalose and hyaluronic acid and its producing method |
| CN101306163A (en) * | 2007-05-14 | 2008-11-19 | 黄小华 | Zhixue shengji powder |
| CN104474536A (en) * | 2014-11-19 | 2015-04-01 | 周清华 | Fresh agrimonia pilosa medicine preparation for treating wounds |
| CN105169377A (en) * | 2015-08-06 | 2015-12-23 | 中国人民解放军济南军区总医院 | Novel application of lysozyme-antibacterial peptide fusion proteins |
-
2020
- 2020-12-03 CN CN202011426374.1A patent/CN112353937A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006069540A1 (en) * | 2004-12-29 | 2006-07-06 | Ocean University Of China | Burn-treating drug delivery system containing trehalose and hyaluronic acid and its producing method |
| CN101306163A (en) * | 2007-05-14 | 2008-11-19 | 黄小华 | Zhixue shengji powder |
| CN104474536A (en) * | 2014-11-19 | 2015-04-01 | 周清华 | Fresh agrimonia pilosa medicine preparation for treating wounds |
| CN105169377A (en) * | 2015-08-06 | 2015-12-23 | 中国人民解放军济南军区总医院 | Novel application of lysozyme-antibacterial peptide fusion proteins |
Non-Patent Citations (1)
| Title |
|---|
| 徐威;王耀斌;周彦宇;赵李剑;刘斌;童春义;: "仙鹤草收敛止血功能及体外抑菌实验", 天然产物研究与开发 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Abd Elgadir et al. | Carica papaya as a source of natural medicine and its utilization in selected pharmacetical applications | |
| CN102058781B (en) | Traditional Chinese medicinal film agent for treating burns and scalds | |
| CN104288504B (en) | A kind of Chinese medicine ointment formulation for treating burn, scald and preparation method thereof | |
| CN104840749B (en) | A kind of externally-applied ointment and preparation method treated skin trauma and be free of heavy metal | |
| CN101797303B (en) | Chinese medicinal plaster for treating burns and scalds | |
| CN104474536A (en) | Fresh agrimonia pilosa medicine preparation for treating wounds | |
| CN104815172A (en) | Scald ointment as well as preparation method and application method of scald ointment | |
| CN103263451B (en) | Traditional Chinese medicine for mainly treating trauma as well as sore and ulcer, preparation method and application of traditional Chinese medicine | |
| CN105194330A (en) | Traditional Chinese medicine composition for promoting wound healing and preparation method of traditional Chinese medicine composition | |
| CN105288703A (en) | Anti-inflammatory and sterilizing non-woven fabric dressing and preparation method | |
| CN107596132A (en) | It is a kind of to be used to treat burn, pharmaceutical composition of scald and its preparation method and application | |
| CN112353937A (en) | Fresh agrimony freeze-dried powder composite preparation | |
| CN106491568A (en) | A kind of marine organisms spray film for treating skin injury and infection and preparation method thereof | |
| CN106806545A (en) | A kind of removing necrosis, promoting granulation herbal composite and preparation method thereof | |
| CN107007761A (en) | A kind of Chinese medicine burn oil and preparation method thereof | |
| CN105497460A (en) | Disinfectant for disinfecting skins | |
| CN105560763A (en) | Traditional Chinese medicine composition skin disinfectant | |
| CN100427118C (en) | Burn and scald medicine | |
| CN111514119A (en) | Adhesive bandage containing industrial hemp root extract and preparation method thereof | |
| CN111991471A (en) | A topical Chinese medicinal preparation for treating knife wound, burn and scald, and its preparation method | |
| CN110624032A (en) | Ointment for treating burns and scalds and preparation method thereof | |
| CN113813308A (en) | Medicine for treating burn and scald and preparation method thereof | |
| CN102423383A (en) | Powder for removing slough and promoting tissue regeneration | |
| CN107050298A (en) | A kind of Chinese medicine paste formulation and preparation method for treating burn and scald skin damaged | |
| CN1401350A (en) | Medicine for treating burns and scald, and producing method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210212 |